Saili Medical: intends to increase capital of its shareholding subsidiary by 42.7429 million yuan.

Saili Medical announced that the company plans to increase its investment in Wuhan Huajiyuan by 42.7429 million yuan. After the capital increase, the company's equity stake in Wuhan Huajiyuan will increase to 41%. At the same time, the company's actual controller, Mr. Wen Wei, intends to use a post-investment valuation of 272 million yuan to acquire 10% of the shares of Wuhan Huajiyuan from shareholder Sun Danping for 27.2 million yuan. The total investment in this transaction by the company and Mr. Wen Wei is 69.9429 million yuan. The target company will be included in the company's consolidated financial statements as a wholly-owned subsidiary in 2026.